AR and prostate carcinoma: AR antagonists induce telomere DNA damage in AR-positive LNCaP prostate cancer cells, and a DDR that has the features of a bona fide telomere DDR, namely, activation of ATM, as indicated by an increase in phosphorylated ATM (pATM) at telomeres [6–8].